2022
Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study
Pahuja M, Leifer ES, Clarke JD, Ahmad T, Daubert MA, Mark DB, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O'Connor CM, Felker GM, Piña IL. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress In Cardiovascular Diseases 2022, 71: 79-85. PMID: 35490873, DOI: 10.1016/j.pcad.2022.04.010.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersEthnicityHeart FailureHumansNatriuretic Peptide, BrainPeptide FragmentsQuality of LifeStroke VolumeConceptsHeart failure hospitalizationNon-black patientsNT-proBNPBlack patientsFailure hospitalizationHigh riskKansas City Cardiomyopathy Questionnaire overall scorePre-specified subgroup analysisGUIDE-IT trialHigher NYHA classReduced ejection fractionNT-proBNP concentrationsHeart failure therapyNon-Hispanic patientsUsual clinical careImportant baseline covariatesQuality of lifeEthnicity-based differencesHF hospitalizationMore comorbiditiesNYHA classCause mortalityTriple therapyFailure therapyEjection fraction
2021
The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial
Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Piña IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM. The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial. ESC Heart Failure 2021, 9: 77-86. PMID: 34784657, PMCID: PMC8787989, DOI: 10.1002/ehf2.13692.Peer-Reviewed Original ResearchConceptsBody mass indexLower body mass indexNT-proBNPAtrial fibrillationN-terminal pro B-type natriuretic peptide valuesMedian body mass indexHigher body mass indexGUIDE-IT trialNT-proBNP targetWorse renal functionNT-proBNP levelsReduced ejection fractionCent of patientsNatriuretic peptide valuesGlomerular filtration rateHeart failure therapyInfluence of comorbiditiesSeverity of illnessEvidence-based therapiesPg/mLCare armLower eGFRRenal dysfunctionUsual careRenal functionDifferences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E, Cooper L, Desvigne‐Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O’Connor C, Felker GM. Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e019712. PMID: 33955231, PMCID: PMC8200692, DOI: 10.1161/jaha.120.019712.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersCanadaCause of DeathFemaleFollow-Up StudiesGuideline AdherenceHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProtein PrecursorsRetrospective StudiesSex DistributionSex FactorsStroke VolumeUnited StatesConceptsReduced ejection fractionNT-proBNP responseGuideline-directed medical therapyGUIDE-IT trialHeart failureEjection fractionNT-proBNPPrognostic valuePg/mLHF hospitalizationMedical therapyEquivalent prognostic valueNT-proBNP reductionNT-proBNP valuesGreater prognostic valueNonischemic causesClinical characteristicsClinical outcomesImproved outcomesLandmark analysisPrognostic biomarkerTherapeutic goalsConclusions MenSecondary analysisWomen